Head & Neck Cancers | Specialty

Head and Neck Cancer: Treatment of Advanced Disease

March 21st 2016

Treatment Approaches in Head and Neck Cancer

March 21st 2016

Multidisciplinary Care in Head and Neck Cancer

March 21st 2016

Diagnosis, Staging, and Prognosis of Head and Neck Cancer

March 21st 2016

Challenges in Implementing Widespread HPV Vaccination

March 21st 2016

HPV Infection in Pathogenesis of Head and Neck Cancers

March 21st 2016

Biology of Head and Neck Squamous Cell Carcinoma

March 21st 2016

Dr. Schoenfeld on Immunologic Effects of Chemotherapy and Radiation in Head and Neck Cancer

March 9th 2016

Jonathan D. Schoenfeld, MD, MPH, physician, assistant professor of Radiation Oncology, Harvard Medical School, Dana Farber Cancer Center on the immunologic effects of chemotherapy and radiation in head and neck cancer.

Dr. Cohen on Lenvatinib in First- or Second-Line Thyroid Cancer

March 9th 2016

Ezra Cohen, MD, Associate Director, Professor of Medicine Moores Cancer Center, UC San Diego, discusses if lenvatinib should be used in the frontline or second-line setting in differentiated thyroid cancer.

Dr. Adelstein on Adjuvant Therapy for Oral Cancer

March 8th 2016

David Adelstein, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses adjuvant therapy options for patients with oral cancer.

Prognostic Significance of Post-Treatment PET/CT Following Salvage Re-irradiation of Head and Neck Cancers

March 7th 2016

Researchers explored the prognostic significance of PET/CT following re-irradiation in patients with head and neck cancer.

Dr. Frakes on Managing Late Toxicities Associated With Treatment for HPV+ Oropharyngeal SCC

February 26th 2016

Jessica Frakes, MD, assistant professor of Radiation Oncology, Department of Radiation Oncology, Moffitt Cancer Center, discusses management of toxicities associated with treatment of patients with HPV-positive oropharyngeal squamous cell carcinoma.

Immunotherapy Continues to Advance in Head and Neck Cancer

February 23rd 2016

An early-stage trial is examining the addition of nivolumab to a cetuximab regimen in head and neck squamous cell carcinoma.

Pazopanib/Cetuximab Combo Shows Promising Efficacy in Advanced HNSCC

February 23rd 2016

The combination of pazopanib (Votrient) and cetuximab (Erbitux) showed a disease control rate of 77% in patients with recurrent or metastatic head and neck squamous cell carcinoma, including patients with cetuximab- or platinum-resistant disease.

Cetuximab Improves Long-Term Control in HPV-Negative Head and Neck Cancer

February 22nd 2016

Among patients with HPV-negative, locoregionally advanced head and neck squamous cell carcinoma with a poor prognosis, adding cetuximab (Erbitux) to induction chemotherapy and hyperfractionated or accelerated chemoradiation therapy produced long-term control.

Dr. Melotek on Cetuximab Added to Chemotherapy and Chemoradiation in Head and Neck Cancer

February 22nd 2016

James Melotek, MD, Radiation and Cellular Oncology, University of Chicago Medicine, discusses an analysis of a phase II study examining the addition of cetuximab to induction chemotherapy and accelerated or hyperfractionated chemoradiation therapy for locoregionally advanced head and neck cancer.

Expert Discusses Promise of Immunotherapy in Head and Neck Cancers

February 22nd 2016

Barbara Burtness, MD, discusses the potential for immunotherapy agents in head and neck cancer.

Martins on Lenvatinib's Significance in Differentiated Thyroid Cancer

February 22nd 2016

Renato G. Martins, MD, discusses the impact of lenvatinib in patients with differentiated thyroid cancer, how and when it should be used in clinical practice, and the future potential for the agent.

Dr. Cabanillas on Lenvatinib as First-Line Therapy for Patients With DTC

February 20th 2016

Maria E. Cabinillas, MD, associate professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses administering lenvatinib (Lenvima) as a first-line therapy for patients with differentiated thyroid cancer (DTC).

Biomarkers Indicate Survival Benefit With Afatinib in HNSCC

February 20th 2016

Both progression-free and overall survival with second-line afatinib (Gilotrif) in recurrent or metastatic head and neck squamous cell carcinoma are associated with several biomarkers.